IL123142A - The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus - Google Patents

The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus

Info

Publication number
IL123142A
IL123142A IL12314296A IL12314296A IL123142A IL 123142 A IL123142 A IL 123142A IL 12314296 A IL12314296 A IL 12314296A IL 12314296 A IL12314296 A IL 12314296A IL 123142 A IL123142 A IL 123142A
Authority
IL
Israel
Prior art keywords
tinnitus
use according
adamantane derivatives
atoms
adamantane
Prior art date
Application number
IL12314296A
Other languages
English (en)
Hebrew (he)
Other versions
IL123142A0 (en
Original Assignee
Tinnitus Forschungs Und Entwic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tinnitus Forschungs Und Entwic filed Critical Tinnitus Forschungs Und Entwic
Publication of IL123142A0 publication Critical patent/IL123142A0/xx
Publication of IL123142A publication Critical patent/IL123142A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12314296A 1995-08-02 1996-07-31 The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus IL123142A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19528388A DE19528388A1 (de) 1995-08-02 1995-08-02 Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
PCT/EP1996/003360 WO1997004762A1 (de) 1995-08-02 1996-07-31 Verwendung von adamantan-derivaten zur behandlung von erkrankungen des innenohrs

Publications (2)

Publication Number Publication Date
IL123142A0 IL123142A0 (en) 1998-09-24
IL123142A true IL123142A (en) 2001-10-31

Family

ID=7768513

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12314296A IL123142A (en) 1995-08-02 1996-07-31 The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus

Country Status (14)

Country Link
US (1) US6066652A (de)
EP (2) EP0834310A1 (de)
JP (1) JP3568039B2 (de)
KR (1) KR100393296B1 (de)
CN (1) CN1142775C (de)
AT (1) ATE163545T1 (de)
AU (1) AU719018B2 (de)
BR (1) BR9609950A (de)
DE (3) DE19528388A1 (de)
DK (1) DK0759295T3 (de)
ES (1) ES2116801T3 (de)
IL (1) IL123142A (de)
PL (1) PL324795A1 (de)
WO (1) WO1997004762A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US7132406B2 (en) 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
ES2292611T3 (es) * 2000-08-08 2008-03-16 Evergreen Packaging International B.V. Procedimiento para la activacion de componentes secuestradores de oxigeno durante un proceso de llenado de cajas de carton con tapa de pico.
EP1190711A1 (de) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Behandlung von Erkrankungen mit Adamantan-derivaten
EP1190709A1 (de) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Behandlung von Tinnitus
EP1201234A3 (de) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Behandlung von Erkrankungen mit Adamantan-derivaten
EP1325743A4 (de) 2000-10-13 2004-12-15 Chugai Pharmaceutical Co Ltd Zusammensetzungen zur verbesserung des fettstoffwechsels
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
JP2006502158A (ja) * 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
JP2008537684A (ja) * 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP2932971A1 (de) * 2005-03-04 2015-10-21 Otonomy, Inc. Ketaminformulierungen
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US20080152694A1 (en) * 2006-07-20 2008-06-26 Neurosystec Corporation Devices, Systems and Methods for Ophthalmic Drug Delivery
WO2008016602A2 (en) * 2006-07-31 2008-02-07 Neurosystec Corporation Free base gacyclidine nanoparticles
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
US20100129467A9 (en) * 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
CN101801366A (zh) * 2007-09-12 2010-08-11 莫茨药物股份两合公司 用于neramexane的逐步增量包装和其在治疗内耳病中的用途
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ, インコーポレイテッド アマンタジン組成物および使用方法
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US4331686A (en) * 1981-08-28 1982-05-25 Pennwalt Corporation Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
PL324795A1 (en) 1998-06-22
DK0759295T3 (da) 1999-01-25
ES2116801T3 (es) 1998-07-16
EP0834310A1 (de) 1998-04-08
AU719018B2 (en) 2000-05-04
DE19680619D2 (de) 1998-10-29
WO1997004762A1 (de) 1997-02-13
CN1194581A (zh) 1998-09-30
KR100393296B1 (ko) 2003-11-17
ATE163545T1 (de) 1998-03-15
KR19990036073A (ko) 1999-05-25
CN1142775C (zh) 2004-03-24
JP2000515486A (ja) 2000-11-21
DE59600105D1 (de) 1998-04-09
MX9800925A (es) 1998-10-31
IL123142A0 (en) 1998-09-24
EP0759295A1 (de) 1997-02-26
BR9609950A (pt) 1999-06-29
EP0759295B1 (de) 1998-03-04
DE19528388A1 (de) 1997-02-06
US6066652A (en) 2000-05-23
JP3568039B2 (ja) 2004-09-22
AU6788296A (en) 1997-02-26

Similar Documents

Publication Publication Date Title
AU719018B2 (en) Use of adamantane derivatives for treating diseases of the inner ear
US6911475B1 (en) Use of nicotine or its derivatives in a drug for treating neurological disease, in particular Parkinson's disease
EP2273975B1 (de) Pharmazeutische lösungen, herstellungsverfahren dafür und therapeutische anwendungen davon
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
Lin et al. Pharmacology of balance and dizziness
JP2008503533A (ja) 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用
US20120035207A1 (en) Use of GABAA Receptor Agonists for the Treatment of Hearing, Vestibular and Attention Disorders, Intention Tremor and Restless Leg Syndrome
CA2376606A1 (en) Active substance combination with clonidine
EP1020189B1 (de) Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
Harris et al. Dose response analysis of pilocarpine-induced ocular hypotension
SK281982B6 (sk) Použitie zlúčenín gabapentínu na výrobu liečiva
CA2228393C (en) Use of adamantane derivatives for treating diseases of the inner ear
Monti et al. The selective histamine H1-receptor agonist 2-(3-trifluoromethylphenyl) histamine increases waking in the rat
Ryan et al. Immunological damage to the inner ear: current and future therapeutic strategies
Kempster et al. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations
MXPA98000925A (en) Use of adamantan derivatives to treat ear inte diseases
US3642994A (en) Therapeutic process using melatonin
Ahlenius et al. Central 5-HT and the respiratory response to acoustic stimulation in awake rats: effects of PCPA, 5-HTP and 8-OH-DPAT
US4783486A (en) Tolrestat for hearing impairment
Gates Innovar treatment for Meniere's disease
Goetting Catamenial exacerbation of action myoclonus: successful treatment with acetazolamide
Broncel et al. Bisoprolol in the treatment of hypertension in the elderly
JP2004510737A (ja) 薬剤の使用
Sataloff et al. Very high-dose streptomycin labyrinthectomy
US10265300B2 (en) Methods of treating seizure disorders

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees